WX UK1

Drug Profile

WX UK1

Alternative Names: WX-UK1

Latest Information Update: 20 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wilex
  • Developer WILEX AG
  • Class Antineoplastics; Aromatic amino acids; Small molecules
  • Mechanism of Action Plasminogen activator inhibitor-1 inhibitors; Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 14 Apr 2014 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 14 Apr 2014 Discontinued - Phase-I/II for Solid tumours in Germany (IV)
  • 25 Jan 2008 Interim efficacy, adverse event, pharmacokinetic and drug interactions data from a phase Ib trial in advanced solid tumours released by Wilex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top